Venatorx Pharmaceuticals

Venatorx Pharmaceuticals is a leading infectious disease pharmaceutical start-up based near Philadelphia, Pennsylvania. With a strong focus on the discovery and development of novel anti-infective drugs, they aim to combat multi-drug-resistant bacterial infections and hard-to-treat viral infections. The name Venatorx originates from the Latin word venator, meaning 'hunter,' symbolizing their core mission of actively pursuing and developing new drugs.

Founded in 2010, Venatorx has established itself as a powerhouse in the industry, with a remarkable in-house research and development organization that has filed over 120 patents. They currently have two lead antibacterial clinical-stage programs, which include intravenous and oral broad-spectrum beta-lactam / beta-lactamase inhibitor combinations. Additionally, Venatorx has advanced their first antiviral compound for Hepatitis B virus inhibitor to Phase 1 clinical development.

They also have discovery-stage programs focused on a new class of antibiotics called Penicillin Binding Protein (PBP) inhibitors. Venatorx Pharmaceuticals has received numerous awards and recognitions for their groundbreaking work, solidifying their position as a leader in the field